Infanrix

Pertussis Toxoid and Pertactin (adsorbed on aluminium hydroxide), the active ingredient in Infanrix, is a preventive vaccine presented as an injectable formulation for intramuscular use. It is intended to protect infants and children against pertussis (whooping cough) by inducing an immune response that generates protective antibodies.

GNH USA supplies Infanrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Infanrix is a preventive vaccine that targets the pertussis bacterium and is used within routine childhood immunisation programmes. - Infants (6 weeks – 6 months): Provides primary immunisation against pertussis. - Children (12‑15 months): Boosts immunity as part of the combined DTPa schedule. - Early childhood (4‑6 years): Maintains protection before school entry.

Infanrix may cause local and systemic reactions following injection.

Common Side Effects: - Pain at injection site: mild to moderate discomfort. - Redness or swelling: localized erythema. - Fever: low‑grade temperature rise. - Irritability: temporary fussiness in infants. - Loss of appetite: reduced feeding for a short period. - Headache: mild headache in older children.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: febrile or non‑febrile convulsions. - Persistent high fever: temperature >40 °C lasting more than 24 hours. - Hypotonic‑hyporesponsive episode: reduced muscle tone and responsiveness. - Severe local reaction: extensive swelling or necrosis. - Guillain‑Barré syndrome: rare autoimmune neuropathy.

Infanrix should be administered according to national immunisation guidelines and with attention to individual health status. - Age restriction: not for infants younger than 6 weeks. - Allergy: avoid if known hypersensitivity to any vaccine component. - Acute illness: defer vaccination during moderate or severe febrile illness. - Immunocompromised: consult a physician before administration. - Concomitant vaccines: follow recommended spacing when given with other injectable vaccines. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that modify immune response.

Major Interactions (Avoid): - Live bacterial vaccines given simultaneously: may reduce efficacy of each product. - High‑dose immunoglobulin therapy within 2 weeks: can neutralise vaccine antigens.

Moderate Interactions (Monitor Closely): - Antipyretics taken prophylactically: may blunt antibody response. - Corticosteroids or immunosuppressants: may diminish immunogenicity. - Blood products administered shortly before or after vaccination: could affect antibody development.